Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese hamster ovary cells.

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.

Dornase alfa is an orphan drug.

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.